Evolus is demonstrating renewed top-line momentum with 21.2% year-over-year revenue growth in 2026Q2, suggesting its core product adoption is accelerating. However, this growth is not translating into profitability, as SG&A expenses consume 67.9% of revenue an...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $0.01+122.3% vs -$0.03 | $84M+3.1% vs $82M |
Q2 2026 May 4, 2026 | -$0.10+28.6% vs -$0.14 | $73M+0.8% vs $73M |
Q2 2026 Mar 3, 2026 | $0.04-26.3% vs $0.06 | $90M+0.9% vs $90M |
Q4 2025 Nov 5, 2025 | -$0.14+26.3% vs -$0.19 | $69M-23.0% vs $90M |
BlackRock Inc. acquired a new stake in shares of Evolus, Inc. (NASDAQ: EOLS) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 4,840,828 shares of the company's stock, valued at approximately $33,595,000. BlackRock Inc. owned approximately 7.35% of Evolus as of its most recent SEC filing.
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture P
The mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Evolus, Inc. (NASDAQ: EOLS - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $8.82 and last traded at $8.78, with a volume of 1320192 shares. The stock had previously closed at $8.39. Wall Street Analysts Forecast Growth EOLS has been the subject
Benchmark EOLS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Evolus, Inc. (EOLS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.00 | $526.84M | -10.00 | 11.61% | -17.38% | — | — | |
| $265.30 | $468.73B | 111.94 | 8.57% | 9.81% | — | — | |
| $115.07 | $6.73B | -28.27 | -79.35% | -1027.25% | -55.42% | — | |
| $0.68 | $87.7M | -4.23 | -10.02% | -9.79% | -47.84% | — | |
| $14.19 | $815.65M | 9.92 | -6.16% | 20.69% | 11.8% | — | |
| $12.79 | $2.79B | 12.18 | 20.19% | 10.56% | 150.2% | — |
Evolus, Inc. (EOLS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Evolus, Inc. (EOLS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Aug 4, 2026·SEC
Jul 8, 2026·SEC
Get notified when EOLS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Evolus, Inc. (EOLS) stock FAQ — growth, dividends, profitability & financials explained
Evolus, Inc. (EOLS) reported $316.5M in revenue for fiscal year 2025.
Evolus, Inc. (EOLS) grew revenue by 11.6% over the past year. This is steady growth.
Evolus, Inc. (EOLS) reported a net loss of $34.3M for fiscal year 2025.
Evolus, Inc. (EOLS) had negative free cash flow of $31.8M in fiscal year 2025, likely due to heavy capital investments.
